Chelsea Therapeutics to Host Conference Call to Discuss First Quarter 2010 Results

CHARLOTTE, N.C., April 22, 2010 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) announced that it will release first quarter
results for the period ended March 31, 2010 after the market closes on Thursday,
April 29, 2010. Chelsea management will host a conference call and live webcast
to discuss these financial results and provide an update on each of its
development programs that afternoon at 5:00 PM ET.

Interested investors may participate in the conference call by dialing
877-638-9567 (domestic) or 720-545-0009 (international). A replay will be
available for one week following the call by dialing 800-642-1687 for domestic
participants or 706-645-9291 for international participants and entering
passcode 70972823 when prompted. Participants may also access both the live and
archived webcast of the conference call on Chelsea's web site at
www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics is a biopharmaceutical development company that acquires
and develops innovative products for the treatment of a variety of human
diseases. Chelsea's most advanced drug candidate, Droxidopa, is an orally active
synthetic precursor of norepinephrine initially being developed for the
treatment of neurogenic orthostatic hypotension. In addition to Droxidopa,
Chelsea is also developing a portfolio of metabolically inert oral antifolate
molecules engineered to have potent anti-inflammatory and anti-tumor activity to
treat a range of immunological disorders, including two clinical stage product
candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior
safety and tolerability, as well as increased potency versus methotrexate (MTX).

This press release contains forward-looking statements regarding future events.
These statements are just predictions and are subject to risks and uncertainties
that could cause the actual events or results to differ materially. These risks
and uncertainties include our need to raise operating capital, our history of
losses, risks and costs of drug development, risk of regulatory approvals, our
reliance on our lead drug candidates Droxidopa and CH-4051, reliance on
collaborations and licenses, intellectual property risks, competition, market
acceptance for our products if any are approved for marketing and reliance on
key personnel including specifically Dr. Pedder.

CONTACT: Chelsea Therapeutics
Investors & Media:
Kathryn McNeil
718-788-2856
mcneil@chelseatherapeutics.com